Know Labs, Inc. announced the publication of its peer-reviewed study in Diabetes Technology & Therapeutics Journal titled, A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor. Diabetes Technology & Therapeutics is a leading, peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software. The published clinical research results demonstrate that Know Labs?

proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms correctly classified an individual?s glycemic status as hyperglycemic, normoglycemic, or hypoglycemic with 93.37% accuracy compared to venous blood glucose values?serving as an early proof-of-concept for a novel, non-invasive diabetes screening device. Results: The findings show that from the total test dataset of 528 paired values, the model correctly classified glycemic status 93.37% of the time as hyperglycemic, normoglycemic, or hypoglycemic. The model achieved sensitivities of 96.63% and 85.51% for normoglycemic and hyperglycemic classes, respectively.

Specificities were 84.51% and 96.92%. More data is required in the hypoglycemic range to evaluate sensitivity and specificity in that glycemic class. Importantly, none of the hyperglycemic values were categorized as hypoglycemia, and none of the hypoglycemic values were categorized as hyperglycemia.

The results support the accuracy of Know Lab?s proprietary non-invasive RF dielectric sensor and ML techniques for glycemic status classification. Further research is needed to enrich the dataset for categorical screening and improve the accuracy and sensitivity of each glycemic status. Efforts led by President, International, Chris Somogyi, will aim to expand this application beyond proof-of-concept alongside potential strategic partners for a Rest of the World (RoW) product that exploits Know Labs?

proprietary RF technology for use as a screening device. This will occur in parallel, as the Company maintains its core focus on bringing the first FDA-cleared non-invasive continuous glucose monitor to the marketplace.